➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim

Last Updated: August 7, 2020

DrugPatentWatch Database Preview

SUDAFED 12 HOUR Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

When do Sudafed 12 Hour patents expire, and what generic alternatives are available?

Sudafed 12 Hour is a drug marketed by Glaxosmithkline and Mcneil Cons and is included in two NDAs.

The generic ingredient in SUDAFED 12 HOUR is pseudoephedrine hydrochloride. There are forty-nine drug master file entries for this compound. Thirty-one suppliers are listed for this compound. Additional details are available on the pseudoephedrine hydrochloride profile page.

Summary for SUDAFED 12 HOUR
Drug patent expirations by year for SUDAFED 12 HOUR
Recent Clinical Trials for SUDAFED 12 HOUR

Identify potential brand extensions & 505(b)(2) entrants

National Heart, Lung, and Blood Institute (NHLBI)Phase 0
Vanderbilt UniversityPhase 0
National Center for Advancing Translational Science (NCATS)Phase 0

See all SUDAFED 12 HOUR clinical trials

US Patents and Regulatory Information for SUDAFED 12 HOUR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glaxosmithkline SUDAFED 12 HOUR pseudoephedrine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 017941-002 Approved Prior to Jan 1, 1982 DISCN Yes No   Start Trial   Start Trial   Start Trial
Mcneil Cons SUDAFED 12 HOUR pseudoephedrine hydrochloride TABLET, EXTENDED RELEASE;ORAL 073585-001 Oct 31, 1991 OTC No Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:


Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.